P50 Component 3: GSK-3 as a Therapeutic Target for FASD

(PI: Lee Anna Cunningham, Co-Is: Allan & Valenzuela) is focused on investigating glycogen synthase kinase-3 (GSK-3) as a potential therapeutic target for reversing behavioral deficits in FASD. Using a combination of pharmacological and genetic approaches, this proposal will test the hypothesis that the inhibition of GSK-3 activity reverses deficits in adult hippocampal neurogenesis and associated learning behaviors in the mouse model of moderate FASD.